Renal cancer vaccine - University of Tubingen

Drug Profile

Renal cancer vaccine - University of Tubingen

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Tubingen
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Renal cancer

Most Recent Events

  • 24 Jan 2017 Discontinued - Phase-I for Renal cancer in Germany (SC)
  • 05 Jan 2001 Suspended-I for Renal cancer in Germany (SC)
  • 19 Apr 1999 Phase-I clinical trials for Renal cancer in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top